Corcept Therapeutics (CORT)
Corcept Therapeutics Market Cap: 340.77M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CORT Market Cap Rankings
| Overall | 43rd percentile | 2644 of 4649 |
| Sector | 57th percentile | 224 of 525 in Healthcare |
| Industry | 66th percentile | 54 of 163 in Biotechnology |
CORT Market Cap Range, Past 5 Years
| Minimum | 40.31M | Jun 2009 |
| Maximum | 356.87M | Mar 2011 |
| Average | 188.95M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these CORT related companies
CORT News
$CORT Low target estimates are 5.00, I don't see anything that should prevent CORT from getting there, at least, this year.
about 2 days ago by Glopolon
about 2 days ago by Glopolon
@jeffreyc69 $CORT, I bought in the 3.80 range and plan on holding, price should begin to trend upward at least by earnings Q2.
about 2 days ago by Glopolon
about 2 days ago by Glopolon
RT @jeffreyc69 $CORT Anbody have any ideas here?????Breakout or fallout??? __ FDA approval, dilution, Korlym on market = bouncy chart.
about 2 days ago by Glopolon
about 2 days ago by Glopolon
$CORT Volume would be nice...........I said yesterday a Flag forming here.......but needs help
about 3 days ago by jeffreyc69
about 3 days ago by jeffreyc69
Market Wrap Video + Additions to Watch List http://stks.co/3x1U including: $AUXL $AVD $CORT $KBH $ULTA $EU
about 5 days ago by StockTiger
about 5 days ago by StockTiger
RT @StockTiger ☞ Market Wrap Video + Additions to Watch List http://stks.co/3wgX including: $AUXL $AVD $CORT $KBH $ULTA $EUO<GREAT ideas!
about 6 days ago by ajb_2010
about 6 days ago by ajb_2010
☞ Market Wrap Video + Additions to Watch List http://stks.co/3wd2 including: $AUXL $AVD $CORT $KBH $ULTA $EUO
about 6 days ago by StockTiger
about 6 days ago by StockTiger
7 breakouts: $ARBA, $CORT (stop: $3.89), $DSW (gap), $PPC (stop: $7.29). Despite losses on the day the breakout candidates were okay.
about 6 days ago by fallondpicks
about 6 days ago by fallondpicks
$CORT filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3vN5
about 7 days ago by MarketBrief
about 7 days ago by MarketBrief
RT @RecogniaEvents $CORT forms bullish "Double Bottom" chart pattern. http://stks.co/3pBH
about 14 days ago by epime7heus
about 14 days ago by epime7heus
$CORT forms bullish "Double Bottom" chart pattern. http://stks.co/3mTy
about 18 days ago by RecogniaEvents
about 18 days ago by RecogniaEvents
$CORT forms bullish "Continuation Wedge" chart pattern. http://stks.co/3fMj
about 25 days ago by RecogniaEvents
about 25 days ago by RecogniaEvents
Corcept Therapeutics Announces First Quarter Results and Corporate and Development Update
May 03, 9:00AM Marketwire
May 03, 9:00AM Marketwire
$CORT " Korlym improved diabetes, promoted weight loss, improved body comp mood and cognition in patients " Maria Fleseriu, M.D.
about 49 days ago by Dariusnejad
about 49 days ago by Dariusnejad
Corcept Therapeutics Announces Exercise of Warrants and Private Placement of New Warrants
Mar 26, 9:01AM Benzinga
Mar 26, 9:01AM Benzinga
Corcept Therapeutics (CORT) Posts Wider than Expected Q4 loss of 12c/Share
Mar 05, 9:15AM Street Insider
Mar 05, 9:15AM Street Insider
Corcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update
Mar 05, 9:00AM Marketwire
Mar 05, 9:00AM Marketwire
Analysts Boost Price Targets on Corcept (CORT) Following FDA Approval of Korlym
Feb 21, 12:14PM Street Insider
Feb 21, 12:14PM Street Insider
Leerink Swann maintains an 'Outperform' on Corcept Therapeutics (CORT); Korlym Approved. Launch To Start On May 1
Feb 21, 12:11PM Street Insider
Feb 21, 12:11PM Street Insider
Corcept Therapeutics (CORT) Rockets On FDA Approval; Analyst Sees Peak U.S. Sales of $300M
Feb 21, 8:15AM Street Insider
Feb 21, 8:15AM Street Insider
Corcept Therapeutics (CORT) Get Boost From Leerink Swann Upgrade - Positive Ahead of PDUFA Date for Korlym
Jan 18, 12:56PM Street Insider
Jan 18, 12:56PM Street Insider
Leerink Swann Upgrades Corcept Therapeutics (CORT) to Outperform; mproved Confidence in Commercial Outlook
Jan 18, 7:05AM Street Insider
Jan 18, 7:05AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CORT | 4.04 | -0.01 | -0.25% | 340.77M |
| CORE | 43.67 | +0.21 | +0.48% | 497.84M |
| COR | 23.96 | -0.09 | -0.37% | 497.17M |
| COPX | 10.97 | -0.12 | -1.08% | |
| COP | 52.11 | -0.03 | -0.06% | 66.68B |
| CWTR | 0.84 | +0.02 | +2.44% | 102.15M |
| CWT | 17.61 | -0.19 | -1.07% | 736.45M |
| CWST | 5.34 | -0.04 | -0.74% | 143.86M |
| CWI | 27.53 | -0.08 | -0.29% | |
| CWH | 18.07 | -0.08 | -0.44% | 1.513B |